Predict your next investment

Venture Capital
sanderling.com

See what CB Insights has to offer

Investments

195

Portfolio Exits

27

Funds

19

About Sanderling Ventures

Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs.

Sanderling Ventures Headquarter Location

400 S. El Camino Real Suite 1200

San Mateo, California, 94402,

United States

650-401-2000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Sanderling Ventures News

ViaCyte Raises $45M in Funding

Jun 19, 2021

ViaCyte , a San Diego CA-based regenerative medicine company, raised $45M in Series D funding. The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures. The company intends to use the funds to advance its portfolio of stem cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. Led by Michael Yang, President and Chief Executive Officer, and Brittany Bradrick, Chief Financial Officer and Chief Operating Officer, ViaCyte is a regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation. The company’s first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes  to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with such companies as CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California.

Sanderling Ventures Investments

195 Investments

Sanderling Ventures has made 195 investments. Their latest investment was in Trefoil Therapeutics as part of their Series A - III on March 3, 2022.

CBI Logo

Sanderling Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/22/2022

Series A - III

Trefoil Therapeutics

$11.97M

Yes

1

6/23/2021

Series B - II

Glycomine

$35M

No

12

6/9/2021

Series D - IV

ViaCyte

$45M

No

14

3/12/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

5/27/2020

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/22/2022

6/23/2021

6/9/2021

3/12/2021

5/27/2020

Round

Series A - III

Series B - II

Series D - IV

Series D

Unattributed VC

Company

Trefoil Therapeutics

Glycomine

ViaCyte

Subscribe to see more

Subscribe to see more

Amount

$11.97M

$35M

$45M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

12

14

10

10

Sanderling Ventures Portfolio Exits

27 Portfolio Exits

Sanderling Ventures has 27 portfolio exits. Their latest portfolio exit was ViaCyte on July 11, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/11/2022

Acquired

$99M

9

8/24/2020

Acquired

$99M

4

6/27/2017

Acquired

$99M

4

2/17/2017

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/14/2016

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/11/2022

8/24/2020

6/27/2017

2/17/2017

12/14/2016

Exit

Acquired

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

9

4

4

10

10

Sanderling Ventures Acquisitions

1 Acquisition

Sanderling Ventures acquired 1 company. Their latest acquisition was Pacira Biosciences on March 05, 2007.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/5/2007

Debt

$99M

$111.25M

Acq - Fin

Date

3/5/2007

Investment Stage

Debt

Companies

Valuation

$99M

Total Funding

$111.25M

Note

Acq - Fin

Sources

Sanderling Ventures Fund History

19 Fund Histories

Sanderling Ventures has 19 funds, including Sanderling I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/30/2008

Sanderling I

Early-Stage Venture Capital

Closed

$7M

1

5/1/2005

Sanderling Beteiligungs

Co-Investment Fund

Closed

$7M

1

5/1/2005

Sanderling VI LP

Early-Stage Venture Capital

Closed

$223M

1

5/1/2005

Sanderling Limited VI

Subscribe to see more

Subscribe to see more

$99M

10

5/1/2004

Sanderling VI Co-Investment LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/30/2008

5/1/2005

5/1/2005

5/1/2005

5/1/2004

Fund

Sanderling I

Sanderling Beteiligungs

Sanderling VI LP

Sanderling Limited VI

Sanderling VI Co-Investment LP

Fund Type

Early-Stage Venture Capital

Co-Investment Fund

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$7M

$7M

$223M

$99M

$99M

Sources

1

1

1

10

10

Sanderling Ventures Team

14 Team Members

Sanderling Ventures has 14 team members, including current Managing Director, Robert McNeil.

Name

Work History

Title

Status

Robert McNeil

Managing Director

Current

Fred A. Middleton

Managing Director

Current

Timothy Mills PhD

Managing Director

Current

Timothy Wollaeger

Managing Director

Current

Donald D Huffman

Chief Financial Officer

Former

Name

Robert McNeil

Fred A. Middleton

Timothy Mills PhD

Timothy Wollaeger

Donald D Huffman

Work History

Title

Managing Director

Managing Director

Managing Director

Managing Director

Chief Financial Officer

Status

Current

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.